Reported about 2 months ago
Viking Therapeutics (VKTX) shares have plummeted despite reporting positive results for its new obesity drug, as rising manufacturing concerns and increasing competition in the GLP-1 weight-loss market have overshadowed its breakthrough. Analysts Julie Hyman and Josh Lipton discuss the implications of the company's phase 1 trial results amid the ObesityWeek conference in San Antonio.
Source: YAHOO